Zobrazeno 1 - 10
of 11
pro vyhledávání: '"Valeria C. Amatto"'
Autor:
Nazia Chaudhuri, Paolo Spagnolo, Claudia Valenzuela, Valeria C. Amatto, Oliver-Thomas Carter, Lauren Lee, Mark Small, Michael Kreuter
Publikováno v:
Respiratory Research, Vol 25, Iss 1, Pp 1-13 (2024)
Abstract Background For patients with interstitial lung diseases (ILDs) presenting with a progressive pulmonary fibrosis (PPF) phenotype, current knowledge of disease characteristics at diagnosis, patient journey, and treatment is limited. This study
Externí odkaz:
https://doaj.org/article/9d6d37ee491b47798782f61659f6e7c7
Autor:
Gary T. Ferguson, Florian Voß, Valeria C. Amatto, Roland Buhl, Jim Reid, Lars Grönke, Andrea Koch, François Maltais, Ulrich Bothner, Lorcan McGarvey
Publikováno v:
Chest. 153:1315-1325
Background Cardiovascular disease is a frequent comorbidity in patients with COPD. Many physicians, particularly pulmonologists, are reluctant to use β-adrenoceptor blocking agents (β-blockers) in patients with COPD, despite their proven effectiven
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::39a79e1da8e3196a2c6de23b39e814ef
https://doi.org/10.1016/j.chest.2018.01.008
https://doi.org/10.1016/j.chest.2018.01.008
Publikováno v:
European Respiratory Journal. 46:1113-1130
Idiopathic pulmonary fibrosis (IPF) is associated with a fatal prognosis and manifests in patients over 60 years old who may have comorbidities. The prevalence and impact of comorbidities on the clinical course of IPF is unclear.This systematic liter
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::353b6ce7d3854eb151c6c0958d75d1e1
https://doi.org/10.1183/13993003.02316-2014
https://doi.org/10.1183/13993003.02316-2014
Autor:
Yihua Zhao, R. Aalbers, M. Reza Maleki-Yazdi, Olaf Schmidt, Alan Hamilton, Leif Bjermer, Stella Waitere-Wijker, Valeria C. Amatto
Publikováno v:
Advances in Therapy
Introduction Combining long-acting muscarinic antagonists (LAMAs) and long-acting β2-agonists (LABAs) is beneficial in chronic obstructive pulmonary disease (COPD), as the two classes of bronchodilator have complementary modes of action. The optimal
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6774844a163efcbabc9743c9cf0e10b0
https://doi.org/10.1007/s12325-015-0239-8
https://doi.org/10.1007/s12325-015-0239-8
Autor:
François, Maltais, Roland, Buhl, Andrea, Koch, Valeria C, Amatto, Jim, Reid, Lars, Grönke, Ulrich, Bothner, Florian, Voß, Lorcan, McGarvey, Gary T, Ferguson
Publikováno v:
Chest. 153(6)
Cardiovascular disease is a frequent comorbidity in patients with COPD. Many physicians, particularly pulmonologists, are reluctant to use β-adrenoceptor blocking agents (β-blockers) in patients with COPD, despite their proven effectiveness in prev
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::62071b7e78998dddaeb4c65c809f6ae1
https://pubmed.ncbi.nlm.nih.gov/29884246
https://pubmed.ncbi.nlm.nih.gov/29884246
Autor:
Lars Grönke, Gary T. Ferguson, Lawrence Korducki, Valeria C. Amatto, Roger Abrahams, M Haensel, Roland Buhl, Stephanie Korn
Publikováno v:
Pneumologie. 70
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::7c9e851d755e1b12f5299f465f49bfe1
https://doi.org/10.1055/s-0036-1572055
https://doi.org/10.1055/s-0036-1572055
Autor:
Gary T. Ferguson, Roland Buhl, Lawrence Korducki, Stephanie Korn, M Henke, Lars Grönke, Valeria C. Amatto, Roger Abrahams
Publikováno v:
Pneumologie. 70
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::2e2c5bdff1f7d87558339e5e31f68790
https://doi.org/10.1055/s-0036-1572083
https://doi.org/10.1055/s-0036-1572083
Publikováno v:
5.1 Airway Pharmacology and Treatment.
Introduction: The efficacy and safety of a new once-daily (QD) fixed-dose combination (FDC) with tiotropium (T), a long-acting muscarinic antagonist, and olodaterol (O), a long-acting β 2 -agonist, was established for the treatment of COPD in the TO
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::6a684bdbb8c11ca7d524d4a2c6cacda2
https://doi.org/10.1183/13993003.congress-2015.pa995
https://doi.org/10.1183/13993003.congress-2015.pa995
Autor:
Valeria C. Amatto, Kay Tetzlaff, Roland Buhl, Lorcan McGarvey, Leif Bjermer, Lawrence Korducki
Publikováno v:
5.1 Airway Pharmacology and Treatment.
Introduction: The TONADO studies (NCT01431274; NCT01431287) established the efficacy and safety of a new once-daily fixed-dose combination (FDC) with tiotropium (T), a long-acting muscarinic antagonist, and olodaterol (O), a long-acting β 2 -agonist
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::1b6a663fd6ac241cc38ed428bcdc91cc
https://doi.org/10.1183/13993003.congress-2015.pa1492
https://doi.org/10.1183/13993003.congress-2015.pa1492
Publikováno v:
Thorax. 70:A135.2-A136
Rationale The efficacy and safety of the once-daily combination of tiotropium (T), a long-acting muscarinic antagonist (LAMA), and olodaterol (O), a long-acting β 2 -agonist (LABA), for the treatment of chronic obstructive pulmonary disease (COPD) h
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::323601bc529e4ff80ecad015be95513d
https://doi.org/10.1136/thoraxjnl-2015-207770.258
https://doi.org/10.1136/thoraxjnl-2015-207770.258